Global Adalimumab, Infliximab and Etanercept Biosimilars Market Report 2024

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2023 – By Product (Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo), By Application (Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 250 | Published : January 2023 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Adalimumab Infliximab and Etanercept Biosimilars Market

Proud Members Of

checkslacipN checkaoirsN checkscipN

Adalimumab, infliximab, and etanercept biosimilars refer to a novel class of medications that work to inhibit the effects of the inflammatory mediator tumour necrosis factor-alpha (TNF-alpha). A chimeric monoclonal antibody against tumour necrosis factor alpha (TNF-alpha) is known as an infliximab biosimilar. Immune system disorders are treated with it.

The main types of products in adalimumab, infliximab, and etanercept biosimilars are adalimumab biosimilars (exemptia, mabura, hyrimoz, hadlima, abrilada, etc.), infliximab biosimilars (inflectra, renflexis, ixifi, avsola), and cipleumab biosimilars (erelzi, eticovo). Adalimumab is a biological drug that works on the immune system to lessen inflammation. The different applications include Crohn’s disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The global adalimumab, infliximab, and etanercept biosimilars market is segmented -

1) By Product: Adalimumab Biosimilars (Exemptia, Mabura, Hyrimoz, Hadlima, Abrilada, Others), Infliximab Biosimilars (Inflectra, Renflexis, Ixifi, Avsola), Cipleumab (Erelzi, Eticovo)

2) By Application: Crohn’S Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

The global adalimumab, infliximab and etanercept biosimilars market size grew from $4.76 billion in 2022 to $6.24 billion in 2023 at a compound annual growth rate (CAGR) of 31.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The market size of the global adalimumab, infliximab and etanercept biosimilars is expected to grow from $25.73 billion in 2027 at a CAGR of 42.5%.

The patent expiration of branded drugs allows biosimilars to enter the adalimumab, infliximab, and etanercept biosimilars market. For instance, in the United States, the FDA approved inflectra, developed by Hospira (a Pfizer Inc. company), for the treatment of various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis, after the patent expiry of the branded drug Remicade. Similarly, Amgen's Enbrel had its patent expire in the EU, and with the expiry of the patent, Benepali (a biosimilar of Enbrel) was approved by the European Commission. Humira's patent expired, and its biosimilars were made available on the market. The FDA has recently (July 2020) approved Hulio, the sixth biosimilar of Humira. Therefore, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade will drive the adalimumab, infliximab, and etanercept biosimilars market demand.

Major players in the adalimumab, infliximab, and etanercept biosimilars market are Zydus Cadila, Sandoz (Novartis), Samsung Bioepis, AbbVie, Amgen, Boehringer Ingelheim, Pfizer, Celltrion, Mylan, Hetero Drugs Ltd., and Glenmark Pharmaceuticals.

The patent extension of Humira (adalimumab) will hamper the adalimumab, infliximab, and etanercept biosimilars market. The patent extension is a strategy to compete with generic and biosimilar products after patent termination. For instance, the patents of Humira, the branded biologic drug manufactured by AbbVie, in the US and EU AbbVie obtained Supplementary Protection Certificates (SPCs) that protected Europe. AbbVie received a patent extension for Humira till 2023 in the US. In pursuit of patent extension, AbbVie also reached settlements with Amgen, Samsung Bioepis, and Mylan to protect Humira sales in the United States. The patent extension of Humira is anticipated to hinder its adalimumab, infliximab, and etanercept biosimilars market growth.

The brand-name versions of biosimilar drugs have high costs, which are now being replaced with biosimilar versions upon their patent’s expiry. The cost of branded biological drugs has almost doubled in recent years. For instance, the cost of Humira, the top-selling drug, increased to more than $72,000 in 2020. The shift to low-cost biosimilar drugs is mainly because there are no clinically relevant differences in safety and efficacy between the biosimilars and the original biologics. The Danish health care system switched almost entirely to adalimumab biosimilars after the patent on the original adalimumab product, Humira, expired in October 2018. The switch to biosimilars led to an 82% decrease in costs for the medication.

In February 2022, Biocon Limited, an India, based biopharmaceutical company specialising in the development of biological drugs, acquired the biosimilar assets of Viatris, Inc., for an amount of $3.34 billion. Through this acquisition, Biocon establishes itself as a distinctive, vertically integrated worldwide biosimilars leader and accelerates the commercialization of its portfolio of current and future biosimilars directly and its product reach around the world. Viatris, Inc., a US-based biopharmaceutical and healthcare company specialising in the development and specialisation of biological and therapeutic agents.

North America was the largest region in the adalimumab, infliximab and etanercept biosimilars market in 2022. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the adalimumab, infliximab, and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA.

The adalimumab, infliximab, and etanercept biosimilars market consists of sales of Amgevita, Hyrimoz, and Idacio. Values in this market are "factory gate values," that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products.

The adalimumab, infliximab, and etanercept biosimilars market research report is one of a series of new reports from The Business Research Company that provides adalimumab, infliximab, and etanercept biosimilars market statistics, including adalimumab, infliximab, and etanercept biosimilars industry global market size, regional shares, competitors with adalimumab, infliximab, and etanercept biosimilars market. This adalimumab, infliximab, and etanercept biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

    Table Of Contents

    1. Adalimumab, Infliximab And Etanercept Biosimilars Market Executive Summary

    2. Table of Contents

    3. List of Figures

    4. List of Tables

    5. Report Structure

    6. Introduction and Market Characteristics

    6.1. General Market Definition

    6.2. Summary

    6.3. Adalimumab, Infliximab And Etanercept Biosimilars Market Definition and Segmentations

    6.4. Market Segmentation By Product

    6.4.1. Adalimumab Biosimilars

    6.4.2. Infliximab Biosimilars

    6.4.3. Etanercept Biosimilars

    6.5. Market Segmentation By Application

    6.5.1. Crohn’s Disease

    6.5.2. Psoriatic Arthritis

    6.5.3. Rheumatoid Arthritis

    6.5.4. Ulcerative Colitis

    6.5.5. Ankylosing Spondylitis

    6.5.6. Plaque Psoriasis

    6.5.7. Other Applications

    6.6. Market Segmentation By Distribution Channel

    6.6.1. Hospital Pharmacies

    6.6.2. Retail Pharmacies

    6.6.3. Online Pharmacies

    7. Major Market Trends

    7.1. Robust Competition in the Marketplace

    7.2. Growing Mergers And Acquisitions

    7.3. Revised FDA Regulations To Facilitate Biosimilar Drug Development

    7.4. Large Number Of Strategic Partnerships

    7.5. Increasing Investments In Biosimilars Market

    8. Global Market Size And Growth

    8.1. Market Size

    8.2. Historic Market Growth, 2016 – 2021, Value ($ Million)

    8.2.1. Market Drivers 2016 – 2021

    8.2.2. Market Restraints 2016 – 2021

    8.3. Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    8.3.1. Market Drivers 2021 – 2026

    8.3.2. Market Restraints 2021 – 2026

    9. Adalimumab, Infliximab and Etanercept Biosimilars Market, Regional Analysis

    9.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    9.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    10. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

    10.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    10.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    10.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distributional Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11. Asia-Pacific Market

    11.1. Summary

    11.2. Asia Pacific Market Overview

    11.2.1. Region Information

    11.2.2. Market Information

    11.2.3. Background Information

    11.2.4. Government Initiatives

    11.2.5. Regulations

    11.2.6. Regulatory Bodies

    11.2.7. Major Associations

    11.2.8. Taxes Levied

    11.2.9. Corporate Tax Structure

    11.2.10. Investments

    11.2.11. Major Companies

    11.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.5. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11.6. Asia Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

    11.7. China Market

    11.8. Summary

    11.9. China Market Overview

    11.9.1. Country Information

    11.9.2. Market Information

    11.9.3. Background Information

    11.9.4. Government Initiatives

    11.9.5. Regulations

    11.9.6. Regulatory Bodies

    11.9.7. Major Associations

    11.9.8. Taxes Levied

    11.9.9. Corporate Tax Structure

    11.9.10. Investments

    11.9.11. Major Companies

    11.10. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.11. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.12. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11.13. India Market

    11.14. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.15. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.16. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11.17. Japan Market

    11.18. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.19. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.20. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11.21. Australia Market

    11.22. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.23. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.24. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11.25. Indonesia Market

    11.26. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.27. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.28. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    11.29. South Korea Market

    11.30. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    11.31. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    11.32. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    12. Western Europe Market

    12.1. Summary

    12.2. Western Europe Market Overview

    12.2.1. Region Information

    12.2.2. Market Information

    12.2.3. Background Information

    12.2.4. Government Initiatives

    12.2.5. Regulations

    12.2.6. Regulatory bodies

    12.2.7. Major Associations

    12.2.8. Taxes Levied

    12.2.9. Corporate Tax Structure

    12.2.10. Investments

    12.2.11. Major Companies

    12.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    12.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    12.5. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    12.6. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

    12.7. UK Market

    12.8. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    12.9. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    12.10. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    12.11. Germany Market

    12.12. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    12.13. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    12.14. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    12.15. France Market

    12.16. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    12.17. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    12.18. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    13. Eastern Europe Market

    13.1. Summary

    13.2. Eastern Europe Market Overview

    13.2.1. Region Information

    13.2.2. Market Information

    13.2.3. Background Information

    13.2.4. Government Initiatives

    13.2.5. Regulations

    13.2.6. Regulatory Bodies

    13.2.7. Major Associations

    13.2.8. Taxes Levied

    13.2.9. Corporate Tax Structure

    13.2.10. Investments

    13.2.11. Major Companies

    13.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    13.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    13.5. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    13.6. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

    13.7. Russia Market

    13.8. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    13.9. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    13.10. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    14. North America Market

    14.1. Summary

    14.2. North America Market Overview

    14.2.1. Region Information

    14.2.2. Market Information

    14.2.3. Background Information

    14.2.4. Government Initiatives

    14.2.5. Regulations

    14.2.6. Regulatory Bodies

    14.2.7. Major Associations

    14.2.8. Taxes Levied

    14.2.9. Corporate tax structure

    14.2.10. Investments

    14.2.11. Major Companies

    14.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    14.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    14.5. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    14.6. North America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

    14.7. USA Market

    14.8. Summary

    14.9. USA Market Overview

    14.9.1. Country Information

    14.9.2. Market Information

    14.9.3. Background Information

    14.9.4. Government Initiatives

    14.9.5. Regulations

    14.9.6. Regulatory Bodies

    14.9.7. Major Associations

    14.9.8. Taxes Levied

    14.9.9. Corporate Tax Structure

    14.9.10. Investments

    14.9.11. Major Companies

    14.10. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    14.11. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    14.12. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    15. South America Market

    15.1. Summary

    15.2. South America Market Overview

    15.2.1. Region Information

    15.2.2. Market Information

    15.2.3. Background Information

    15.2.4. Government Initiatives

    15.2.5. Regulations

    15.2.6. Regulatory Bodies

    15.2.7. Major Associations

    15.2.8. Taxes Levied

    15.2.9. Corporate Tax Structure

    15.2.10. Investments

    15.2.11. Major Companies

    15.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    15.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    15.5. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    15.6. South America Adalimumab, Infliximab and Etanercept Biosimilars Market: Country Analysis

    15.7. Brazil Market

    15.8. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    15.9. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    15.10. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    16. Middle East Market

    16.1. Summary

    16.2. Middle East Market Overview

    16.2.1. Region Information

    16.2.2. Market Information

    16.2.3. Background Information

    16.2.4. Government Initiatives

    16.2.5. Regulations

    16.2.6. Regulatory Bodies

    16.2.7. Major Associations

    16.2.8. Taxes Levied

    16.2.9. Corporate Tax Structure

    16.2.10. Investments

    16.2.11. Major Companies

    16.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    16.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    16.5. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    17. Africa Market

    17.1. Summary

    17.2. Africa Market Overview

    17.2.1. Region Information

    17.2.2. Market Information

    17.2.3. Background Information

    17.2.4. Government Initiatives

    17.2.5. Regulations

    17.2.6. Regulatory Bodies

    17.2.7. Major Associations

    17.2.8. Taxes Levied

    17.2.9. Corporate Tax Structure

    17.2.10. Investments

    17.2.11. Major Companies

    17.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic Market Growth, 2016 – 2021, Value ($ Million)

    17.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast Market Growth, 2021 – 2026, 2031F Value ($ Million)

    17.5. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, Value ($ Million)

    18. Competitive Landscape And Company Profiles

    19. Company Profiles

    19.1. Biogen

    19.1.1. Company Overview

    19.1.2. Products And Services.

    19.1.3. Business Strategy

    19.1.4. Financial Overview

    19.2. Novartis AG (Sandoz)

    19.2.1. Company Overview

    19.2.2. Products And Services.

    19.2.3. Business Strategy

    19.2.4. Financial Overview

    19.3. Pfizer Inc.

    19.3.1. Company Overview

    19.3.2. Products And Services

    19.3.3. Business Strategy

    19.3.4. Financial Overview

    19.4. Amgen Inc

    19.4.1. Company Overview

    19.4.2. Products And Services.

    19.4.3. Business Strategy

    19.4.4. Financial Overview

    19.5. Celltrion

    19.5.1. Company Overview

    19.5.2. Products And Services

    19.5.3. Business Strategy

    19.5.4. Financial Overview

    20. Pipeline Analysis

    21. Key Mergers And Acquisitions In The Market

    21.1. Fresenius Kabi Acquired mAbxience

    21.2. Biocon Biologics to Acquire Viatris Biosimilars Business

    21.3. Celltrion Acquired Assets Of Takeda Pharmaceuticals

    21.4. Amgen Acquired Japanese JV with Astellas

    21.5. True North Acquired Stake In Biocon Biologics Ltd.

    21.6. Biocon Acquired Research and Development (R&D) Facility from Pfizer Healthcare India

    21.7. Ligand Pharmaceuticals Acquired Pfenex

    21.8. PAG Acquired Hisun BioRay Bio-pharmaceutical Co., Ltd.

    21.9. Samsung Bioepis Enters Into An Agreement With C-Bridge Capital

    21.10. Fuji Pharma Co., Ltd. Acquired Stake In Alvotech

    21.11. Biocon Merged With Sandoz

    22. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Opportunities And Strategies

    22.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 – Countries Offering Most New Opportunities

    22.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market In 2026 – Segments Offering Most New Opportunities

    22.3. Global Adalimumab, Infliximab And Etanercept Biosimilars Market In 2026 – Growth Strategies

    22.3.1. Market Trend Based Strategies

    22.3.2. Competitor Strategies

    23. Adalimumab, Infliximab and Etanercept Biosimilars Market, Conclusions And Recommendations

    23.1. Conclusions

    23.2. Recommendations

    23.2.1. Product

    23.2.2. Place

    23.2.3. Price

    23.2.4. Promotion

    23.2.5. People

    24. Appendix

    24.1. Market Data Sources

    24.2. Research Methodology

    24.3. Currencies

    24.4. The Business Research Company

    24.5. Copyright and Disclaimer

List Of Tables

    Table 1: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 2: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 3: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 4: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 6: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 7: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 8: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 9: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 10: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 11: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 12: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 13: Asia-Pacific Population By Age Group, By Country, 2016-2026, Thousands
  • Table 14: Asia-Pacific GDP Per Capita, By Country, 2016-2021, $
  • Table 15: Asia-Pacific Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 16:  Asia-Pacific Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 17: Asia-Pacific, Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 18: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 19: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 20: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 21: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 22: China Population By Age Group, 2016-2026, Thousands
  • Table 23: China GDP Per Capita, 2016-2021, $
  • Table 24:  China Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 25: China Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 26: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 27: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 28: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 29: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 30: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 31: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 32: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 33: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 34: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 35: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 36: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 37: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 38: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 39: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 40: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 41: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 42: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 43: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 44: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 45: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 46: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 47: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 48: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 49: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 50: Western Europe Population By Age Group, By Country, 2016-2026, Thousands
  • Table 51: Western Europe GDP Per Capita, By Country, 2016-2021, $
  • Table 52:  Western Europe Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 53:  Western Europe Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 54: Western Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 55: Western Smart Europe Washing Machines Market, Historic, 2016 – 2021, $ Million
  • Table 56: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 57: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 58: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 59: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 60: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 61: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 62: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 63: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 64: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 65: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 66: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 67: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 68: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 69: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 70: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 71: Eastern Europe Population By Age Group, By Country, 2016-2026, Thousands
  • Table 72: Eastern Europe GDP Per Capita, By Country, 2016-2021, $
  • Table 73:  Eastern Europe Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 74:  Eastern Europe Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 75: Eastern Europe Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 76: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 77: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 78: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 79: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 80: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 81: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 82: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 83: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 84: North America Population By Age Group, By Country, 2016-2026, Thousands
  • Table 85: North America GDP Per Capita, By Country, 2016-2021, $
  • Table 86:  North America Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 87:  North America Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 88: North America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 89: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 90: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 91: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 92: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 93: USA Population By Age Group, 2016-2026, Thousands
  • Table 94: USA GDP Per Capita, 2016-2021, $
  • Table 95:  USA Public Healthcare Expenditure And Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 96: USA Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 97: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 98: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 99: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 100: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 101: South America Population By Age Group, By Country, 2016-2026, Thousands
  • Table 102: South America GDP Per Capita, By Country, 2016-2021, $
  • Table 103:  South America Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 104:  South America Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 105: South America Healthcare Services Market Size, By Country, 2016-2026, $ Billion
  • Table 106: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 107: South America Washing Machines Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 108: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 109: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 110: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 111: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 112: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 113: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 114: Middle East Population By Age Group, By Country, 2016-2026, Thousands
  • Table 115: Middle East GDP Per Capita, By Country, 2016-2021, $
  • Table 116:  Middle East Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 117:  Middle East Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 118: Middle East Healthcare Services Market Size, 2016-2026, $ Billion
  • Table 119: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 120: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 121: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 122: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 123: Africa Population By Age Group, By Country, 2016-2026, Thousands
  • Table 124: Africa GDP Per Capita, By Country, 2016-2021, $
  • Table 125:  Africa Public Healthcare Expenditure, 2015-2020, $ Billion
  • Table 126:  Africa Private Healthcare Expenditure, 2015-2020, $ Billion
  • Table 127: Africa Healthcare Services Market Size, 2016-2026, $ Billion
  • Table 128: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Table 129: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Table 130: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Table 131: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, $ Million
  • Table 132: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
  • Table 133: Biogen – Financial Performance, 2017– 2021, $ Billion
  • Table 134 Novartis – Financial Performance, 2017– 2021, $ Billion
  • Table 135: Pfizer – Financial Performance, 2017– 2021, $ Billion
  • Table 136 Amgen – Financial Performance, 2017– 2021, $ Billion
  • Table 137: Celltrion – Financial Performance, 2017– 2021, $ Billion
  • Table 138: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), 2021 – 2026, By Country
  • Table 139: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Product, 2021 – 2026
  • Table 140: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Application, 2021 – 2026
  • Table 141: Global Adalimumab, Infliximab and Etanercept Biosimilars Market Size Gain ($ Million), Segmentation By Distribution Channel, 2021 – 2026
  • Table 142: Adalimumab, Infliximab and Etanercept Biosimilars Market Data Sources

List Of Figures

    Figure 1: Geographic Regions Covered
  • Figure 2: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Product
  • Figure 3: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Application
  • Figure 4: Global Adalimumab, Infliximab And Etanercept Biosimilars Market Segmentation By Distribution Channel
  • Figure 5: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 6: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 7: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Region, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 8: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, By Country, Historic and Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 9: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 10: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 11: Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 12: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 13: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 14: Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 15: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 16: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 17: China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 18: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 19: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 20: India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 21: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 22: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 23: Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 24: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 25: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 26: Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 27: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 28: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 29: Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 30: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 31: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 32: South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 33: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 34: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 35: Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 36: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 37: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 38: UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 39: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 40: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 41: Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 42: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 43: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 44: France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 45: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 46: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 47: Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 48: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 49: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 50: Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 51: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 52: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 53: North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 54: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 55: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 56: USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 57: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 58: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 59: South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 60: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 61: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 62: Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 63: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 64: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 65: Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 66: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Historic, 2016 – 2021, $ Million
  • Figure 67: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Forecast, 2021 – 2026, 2031F, $ Million
  • Figure 68: Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic And Forecast, 2016 – 2021, 2026F, 2031F, %
  • Figure 69: Global Adalimumab, Infliximab And Etanercept Biosimilars Market, Key Competitor Estimated Market Shares, 2021, Percentage (%)
  • Figure 70: Biogen – Financial Performance, $ Billion
  • Figure 71: Novartis – Financial Performance, 2017– 2021, $ Billion
  • Figure 72: Pfizer – Financial Performance, 2017– 2021, $ Billion
  • Figure 73: Amgen – Financial Performance, 2017– 2021, $ Billion
  • Figure 74: Celltrion – Financial Performance, 2017– 2021, $ Billion
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report